Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Ablynx NV Snapshot 6
Ablynx NV Overview 6
Key Information 6
Key Facts 6
Ablynx NV - Research and Development Overview 7
Key Therapeutic Areas 7
Ablynx NV - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Pipeline Products - Partnered Products 12
Partnered Products/Combination Treatment Modalities 13
Pipeline Products - Out-Licensed Products 14
Out-Licensed Products/Combination Treatment Modalities 15
Ablynx NV - Pipeline Products Glance 16
Ablynx NV - Late Stage Pipeline Products 16
Phase III Products/Combination Treatment Modalities 16
Ablynx NV - Clinical Stage Pipeline Products 17
Phase II Products/Combination Treatment Modalities 17
Phase I Products/Combination Treatment Modalities 18
Ablynx NV - Early Stage Pipeline Products 19
Preclinical Products/Combination Treatment Modalities 19
Discovery Products/Combination Treatment Modalities 20
Ablynx NV - Drug Profiles 21
caplacizumab 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
ALX-0061 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
ozoralizumab 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
ALX-0171 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
ALX-0141 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Monoclonal Antibodies for Immunology and Oncology 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Monoclonal Antibodies for Inflammation and Osteoarthritis 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Monoclonal Antibodies for Multiple Sclerosis 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Monoclonal Antibody for Undisclosed Indication 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Monoclonal Antibody to Target c-Met for Multiple Myeloma 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
TLC-520 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Monoclonal Antibodies to Agonize GITR for Immunology and Oncology 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Monoclonal Antibody 1 for Oncology 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Monoclonal Antibody 2 for Oncology 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Ablynx NV - Pipeline Analysis 39
Ablynx NV - Pipeline Products by Target 39
Ablynx NV - Pipeline Products by Route of Administration 40
Ablynx NV - Pipeline Products by Molecule Type 41
Ablynx NV - Pipeline Products by Mechanism of Action 42
Ablynx NV - Recent Pipeline Updates 43
Ablynx NV - Dormant Projects 51
Ablynx NV - Discontinued Pipeline Products 52
Discontinued Pipeline Product Profiles 52
BI-1034020 52
Ablynx NV - Company Statement 53
Ablynx NV - Locations And Subsidiaries 55
Head Office 55
Other Locations & Subsidiaries 55
Appendix 56
Methodology 56
Coverage 56
Secondary Research 56
Primary Research 56
Expert Panel Validation 56
Contact Us 56
Disclaimer 57

List of Tables
Ablynx NV, Key Information 6
Ablynx NV, Key Facts 6
Ablynx NV - Pipeline by Indication, 2016 8
Ablynx NV - Pipeline by Stage of Development, 2016 10
Ablynx NV - Monotherapy Products in Pipeline, 2016 11
Ablynx NV - Partnered Products in Pipeline, 2016 12
Ablynx NV - Partnered Products/ Combination Treatment Modalities, 2016 13
Ablynx NV - Out-Licensed Products in Pipeline, 2016 14
Ablynx NV - Out-Licensed Products/ Combination Treatment Modalities, 2016 15
Ablynx NV - Phase III, 2016 16
Ablynx NV - Phase II, 2016 17
Ablynx NV - Phase I, 2016 18
Ablynx NV - Preclinical, 2016 19
Ablynx NV - Discovery, 2016 20
Ablynx NV - Pipeline by Target, 2016 39
Ablynx NV - Pipeline by Route of Administration, 2016 40
Ablynx NV - Pipeline by Molecule Type, 2016 41
Ablynx NV - Pipeline Products by Mechanism of Action, 2016 42
Ablynx NV - Recent Pipeline Updates, 2016 43
Ablynx NV - Dormant Developmental Projects,2016 51
Ablynx NV - Discontinued Pipeline Products, 2016 52
Ablynx NV, Subsidiaries 55

List of Figures
Ablynx NV - Pipeline by Top 10 Indication, 2016 8
Ablynx NV - Pipeline by Stage of Development, 2016 10
Ablynx NV - Monotherapy Products in Pipeline, 2016 11
Ablynx NV - Partnered Products in Pipeline, 2016 12
Ablynx NV - Out-Licensed Products in Pipeline, 2016 14
Ablynx NV - Pipeline by Target, 2016 39
Ablynx NV - Pipeline by Route of Administration, 2016 40
Ablynx NV - Pipeline by Molecule Type, 2016 41
Ablynx NV - Pipeline Products by Mechanism of Action, 2016 42